Insight Molecular Diagnostics annual gross margin
2020
2021
2022
2023
2024
2025
Insight Molecular Diagnostics Gross Margin Growth & History (IMDX)
Insight Molecular Diagnostics's gross margin was 56.67% for fiscal 2025.
View full Insight Molecular Diagnostics company overviewInsight Molecular Diagnostics annual gross margin history
| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 56.67% | +17.33 pp |
| 2024 | 2024-12-31 | 39.34% | +11.86 pp |
| 2023 | 2023-12-31 | 27.48% | +29.36 pp |
| 2022 | 2022-12-31 | −1.88% | −66.48 pp |
| 2021 | 2021-12-31 | 64.60% | +117.15 pp |
| 2020 | 2020-12-31 | −52.55% | — |
Insight Molecular Diagnostics quarterly gross margin
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 65.69% | +0.44 pp |
| Q1 2026 | 2026-03-31 | 46.88% | −15.10 pp |
| Q4 2025 | 2025-12-31 | 43.55% | +3.51 pp |
| Q3 2025 | 2025-09-30 | 53.46% | +9.98 pp |
| Q2 2025 | 2025-06-30 | 65.25% | +17.17 pp |
| Q1 2025 | 2025-03-31 | 61.97% | +36.41 pp |
| Q4 2024 | 2024-12-31 | 40.04% | +77.30 pp |
| Q3 2024 | 2024-09-30 | 43.48% | −14.33 pp |
| Q2 2024 | 2024-06-30 | 48.08% | −10.67 pp |
| Q1 2024 | 2024-03-31 | 25.57% | +22.20 pp |
| Q4 2023 | 2023-12-31 | −37.26% | −27.41 pp |
| Q3 2023 | 2023-09-30 | 57.81% | +459.30 pp |
| Q2 2023 | 2023-06-30 | 58.75% | +45.67 pp |
| Q1 2023 | 2023-03-31 | 3.37% | −61.63 pp |
| Q4 2022 | 2022-12-31 | −9.85% | +78.15 pp |
| Q3 2022 | 2022-09-30 | −401.49% | −382.08 pp |
| Q2 2022 | 2022-06-30 | 13.08% | +6.05 pp |
| Q1 2022 | 2022-03-31 | 65.00% | +73.29 pp |
| Q3 2021 | 2021-09-30 | −88.01% | +67.24 pp |
| Q2 2021 | 2021-06-30 | −19.41% | — |
| Q1 2021 | 2021-03-31 | 7.03% | — |
| Q3 2020 | 2020-09-30 | −8.29% | — |
| Q2 2020 | 2020-06-30 | −155.24% | — |
Insight Molecular Diagnostics gross margin trends
Over the last five reported fiscal years, Insight Molecular Diagnostics's gross margin increased from −52.55% to 56.67%, a change of +109.22 percentage points. The latest reported quarter, Q2 2026, shows 65.69%.
About the metric
What gross margin means
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
Calculation and source
How gross margin is calculated
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Insight Molecular Diagnostics filings at SEC.gov ↗